

## Original Research Article

# Neutrophil-lymphocyte ratio as a prognostic tool for the evaluation of laryngeal carcinoma

Ashish Sharma, S. K. Kanaujia, Sandeep Kaushik, Amrita Srivastava\*

Department of Otorhinolaryngology, GSVM Medical College, Kanpur, Uttar Pradesh, India

**Received:** 30 December 2020

**Revised:** 14 February 2021

**Accepted:** 15 February 2021

### \*Correspondence:

Dr. Amrita Srivastava,

E-mail: [dramritasrivastava@gmail.com](mailto:dramritasrivastava@gmail.com)

**Copyright:** © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### ABSTRACT

**Background:** The objective of the study was to review the neutrophil lymphocyte ratio (NLR) as a prognostic tool in carcinoma larynx.

**Methods:** Patients who were fulfilling inclusion criteria after screening were selected for study. On the basis of cutoff pretreatment NLR (<3 or >3) divided into two groups high pretreatment NLR and low pretreatment NLR. Patient undergo chemo or radiotherapy and at the end of follow up these two group NLR were compared with tumor negative prognostic score, survival at the end of follow up, resolving of symptoms, staging change, tumor regression and overall prognosis at the end of follow up were assessed.

**Results:** Mean value of tumor negative prognostic score of early carcinoma with low NLR, early carcinoma with high NLR, late carcinoma with low NLR and late carcinoma with High NLR were  $13.833 \pm 2.80$ ,  $24.04 \pm 4.5538$ ,  $37.833 \pm 8.68$  and  $55.33 \pm 6.429$  respectively. 10 (17.5%) patients with high NLR show more than 50% tumor regression while 17 (29.82%) with high NLR show <50% tumor regression. 26 (45.61%) patients with low NLR show >50% tumor regression and 4 (7.01%) show <50% tumor regression.

**Conclusions:** It was concluded in our study that pretreatment NLR is an acceptable prognostic tool in carcinoma larynx. High NLR was associated with poor prognosis and low NLR was associated with better prognosis.

**Keywords:** Neutrophil/lymphocyte ratio, Laryngeal carcinoma, Tumor negative prognostic score

### INTRODUCTION

Laryngeal carcinoma is the frequent site of malignancy in the region of head and neck. It has a high incidence among head neck cancer. Laryngeal tumours usually presents itself in old age group. Its incidence now rise due to increase addiction of smoking which is one of the predisposing factor. Other etiological factors associated with laryngeal carcinoma are addiction of alcohol, occupational exposure, previous radiation for other head neck cancer. Various prognostic factors are routinely used such as gender of patients, age, addiction of tobacco, smoking, cartilage of larynx invasion, staging, positive surgical margins for predicting disease progression. The variant which encountered most is squamous cell

carcinoma. Prognosis can be commented by knowing variant of carcinoma, grade, size, staging, cartilage invasion, metastasis but evaluation of these are not easy, cheaper and repeatable so there is a need of spotting of new tumor marker which give us fair clue about prognosis even before the commencement of intervention.

### Objective

In this study, it was aimed to review the neutrophil lymphocyte ratio (NLR) as a prognostic tool in carcinoma larynx and to evaluate the correlation of NLR with TNM staging of carcinoma larynx. Prognosis and its correlation (if any) with other prognostic factors.

**METHODS**

The proposed study was Hospital based prospective study and was conducted in the department of ENT, GSVM Medical College and LLR associated Hospitals from January 2019 to October 2020 on patients of laryngeal carcinoma admitted in OPD and causality department. Study was conducted on 65 patients of diagnosed carcinoma larynx showing clinical symptoms which affect quality of life.

Patient after screening were selected for study and divided into two groups on the basis of pretreatment cutoff (>3 (n=35) or < 3 (n=30)) NLR ratio then patient undergo chemo or radiotherapy and at the end of follow up compare these pretreatment NLR value with quality of life score (Tumor negative prognostic score), survival at the end of follow up, staging change (Early carcinoma include stage I and II while Late carcinoma include stage III and IV), resolving of symptoms, tumor regression on the basis of CT scan finding (>50% regression is significant), overall prognosis.

**Study period**

About 22 months from January 2019 to October 2020, including development of study tools, collection of data, analysis and presentation.

**Study design**

Comparative, prospective hospital based observational study.

It is a hospital based observational study conducted over patients of diagnosed laryngeal carcinoma. Detailed history was taken, clinical examination was performed, histopathological examination was done, relevant laboratory and radiological investigations were done and data was recorded on the case sheet.

**Ethical approval**

The Ethics committee GSVM Medical College approves the above mentioned study.

**Inclusion criteria**

Clinically diagnosed patient of squamous cell carcinoma of larynx.

**Exclusion criteria**

Critically ill /terminal patient. Histopathological variants of carcinoma larynx. Synchronous primaries present.

Questionnaire was develop to assess tumour negative prognostic score.

**Four point scale**

- (3) Extremely troubled (severe)
- (2) Moderately troubled (moderate)
- (1) Somewhat troubled (mild)
- (0) Not troubled

**Table 1: Questionnaire to asses tumour negative prognostic score.**

|                                  | Not trouble | Somewhat trouble | Moderately trouble | Extremely trouble |
|----------------------------------|-------------|------------------|--------------------|-------------------|
| Swallowing problem               | 0           | 1                | 2                  | 3                 |
| Pain                             | 0           | 1                | 2                  | 3                 |
| Vomiting                         | 0           | 1                | 2                  | 3                 |
| RT feed                          | 0           | 1                | 2                  | 3                 |
| Change in voice                  | 0           | 1                | 2                  | 3                 |
| Hoarseness                       | 0           | 1                | 2                  | 3                 |
| Voice fatigue                    | 0           | 1                | 2                  | 3                 |
| Cannot speak due to tracheostomy | 0           | 1                | 2                  | 3                 |
| Breathing problem                | 0           | 1                | 2                  | 3                 |
| Mild dyspnea                     | 0           | 1                | 2                  | 3                 |
| Dyspnea during passive work      | 0           | 1                | 2                  | 3                 |
| Dyspnea during active work       | 0           | 1                | 2                  | 3                 |
| Dyspnea at rest                  | 0           | 1                | 2                  | 3                 |
| Pain                             | 0           | 1                | 2                  | 3                 |
| Affected                         | 0           | 1                | 2                  | 3                 |
| Disturbing                       | 0           | 1                | 2                  | 3                 |
| Hamper in daily activity         | 0           | 1                | 2                  | 3                 |
| Sleep problem                    | 0           | 1                | 2                  | 3                 |
| Lack of sleep                    | 0           | 1                | 2                  | 3                 |
| Wake during night                | 0           | 1                | 2                  | 3                 |
| Difficulty getting to sleep      | 0           | 1                | 2                  | 3                 |

Continued.

|                            | Not trouble | Somewhat trouble | Moderately trouble | Extremely trouble |
|----------------------------|-------------|------------------|--------------------|-------------------|
| <b>Activity limitation</b> |             |                  |                    |                   |
| <b>Physical</b>            | 0           | 1                | 2                  | 3                 |
| <b>Social</b>              | 0           | 1                | 2                  | 3                 |
| <b>Occupation</b>          | 0           | 1                | 2                  | 3                 |
| <b>Emotional function</b>  |             |                  |                    |                   |
| <b>Irritable</b>           | 0           | 1                | 2                  | 3                 |
| <b>Frustrated</b>          | 0           | 1                | 2                  | 3                 |
| <b>Restless</b>            | 0           | 1                | 2                  | 3                 |
| <b>Embarrassed</b>         | 0           | 1                | 2                  | 3                 |
| <b>Practical problems</b>  |             |                  |                    |                   |
| <b>Fatigue</b>             | 0           | 1                | 2                  | 3                 |
| <b>Tiredness</b>           | 0           | 1                | 2                  | 3                 |
| <b>Poor concentration</b>  | 0           | 1                | 2                  | 3                 |
| <b>Reduce productivity</b> | 0           | 1                | 2                  | 3                 |
| <b>Headache</b>            | 0           | 1                | 2                  | 3                 |

**Disease severity**

- Grade I (0-21) - Mild
- Grade II (22-42) - Moderate
- Grade III (43-63) - Severe
- Grade IV (64-84) - Very severe

**Statistical analysis**

The data obtained from the case sheet was recorded and tabulated on MS excel work – sheet and were analyzed using appropriate statistical tools (average, standard deviation, percentages, test such as chi- square, paired and unpaired t test) obtained were compared with the previously published authentic study and inferences were drawn accordingly.

**RESULTS**

10 (17.5%) patients with high NLR show more than 50% tumor regression while 17 (29.82%) with high NLR show <50% tumor regression. 26 (45.61%) patients with low NLR show >50% tumor regression and 4 (7.01%) show <50% tumor regression, on applying Chi-Square test association is considered to be statistically significant (Table 1). Out of 65 patients, 57 (87.69%) patients survive while 8 (12.3%) patients died.

**Table 2: Relationship between pretreatment NLR and tumour regression.**


|                                            | High NLR    | Low NLR     |
|--------------------------------------------|-------------|-------------|
| <b>Tumour regression present (&gt;50%)</b> | 10 (17.54%) | 26 (45.61%) |
| <b>Tumour regression (&lt;50%)</b>         | 17 (29.82%) | 4 (7.01%)   |

After applying chi square test (12.98 with 1 degree of freedom) between tumor regression and NLR value, the association is considered to be statistically significant.

**Table 3: Relationship of NLR with QOL at the end of follow up.**

|                  | Low NLR      | High NLR     | P value |
|------------------|--------------|--------------|---------|
| <b>QOL Score</b> | 17.466±6.027 | 40.259±13.25 | <0.0001 |

On comparing QOL score in high and low NLR the difference comes out to be significant (p <0.0001) on applying T test.




**Figure 1: Relationship of QOL score with NLR and staging of laryngeal carcinoma.**

On comparing QOL score in low NLR range of early and late carcinoma the difference comes out to be significant (p<0.0001) on applying T-test. On comparing QOL score in high NLR range of early and late carcinoma the difference comes out to be significant (p<0.0001) on applying T-test.

Mean±SD of high NLR group was found 6.31±3.34 while Mean±SD of low NLR group was found 2.227±0.625. 30 (100 %) patients with low NLR who took part in the study survive at the end of the follow up while only 77.14% patients with high NLR survive at the end. Mean value of QOL score (tumor negative prognostic score) of low NLR and high NLR were 17.466±6.027 and 40.259±13.25 respectively (Table 2). At the end of follow up, early carcinoma (stage 1 and stage 2) comprises 73.84% patients while late carcinoma (stage 3 and stage 4) comprises

13.84% patients and 12.30% patients died during follow up. Mean Value of QOL Score of early carcinoma with low NLR, early carcinoma with high NLR, late carcinoma with low NLR and late carcinoma with high NLR were  $13.833 \pm 2.80$ ,  $24.04 \pm 4.5538$ ,  $37.833 \pm 8.68$  and  $55.33 \pm 6.429$  respectively (Figure 1). 73.84% patients of high NLR group show addiction of smoking while only 9.23% patients of low NLR group show positive history of addiction of smoking. On applying Chi-Square test (p value=0.0031) the association between Smoking and NLR value is considered to be statistically significant (Figure 2). 55.38% Patients of high NLR group show addiction of alcohol while 9.23% patients of Low NLR group show addiction of alcohol. On applying Chi-Square Test the association between alcohol intake and NLR value is considered to be statistically significant.



**Figure 2: Relation of NLR with smoking of study subjects.**

On applying Chi-Square test (p value=0.0031) the association between smoking and NLR value is considered to be statistically significant.

## DISCUSSION

Many markers are used in laryngeal carcinoma as a prognostic factor. Eskiizmir et al studied neutrophil lymphocyte ratio and derived neutrophil lymphocyte ratio were predictive factors for stage, lymph node metastasis, and distant metastasis.<sup>1</sup> Patients with high neutrophil lymphocyte ratio value ( $\geq 4$ ) had a poor prognosis when compared with patients with low neutrophil lymphocyte ratio value (5 year, overall survival: 69.0% versus 31.1%,  $p < 0.001$ ; 5 year, disease free survival: 70.0% versus 32.7%,  $p < 0.001$ ; 5 year, locoregional recurrence free survival: 69.7% versus 32.0%,  $p < 0.001$ ). Furthermore, neutrophil lymphocyte ratio was an independent prognostic factor for 5 year: overall survival (HR=2.396; 95% CI 1.408-4.077;  $p = 0.001$ ), disease free survival (HR=2.246; 95% CI 1.322-3.816;  $p = 0.006$ ) and locoregional recurrence free survival (HR=2.210; 95% CI 1.301-3.753;  $p = 0.003$ ).

Yilmaz et al observe the relationship of NLR with the degree of differentiation of tumor, significant results were found.<sup>2</sup> Significant differences were observed between well-differentiated SCC and moderately differentiated and

between well-differentiated and poorly differentiated SCC. NLR was significantly higher in patients with poor differentiation. When NLR was compared with clinical stage, it was found to be significantly higher in stage IV laryngeal cancer than stage III.

Duzlu et al take 65 cases in the study and 42 cases in control group meeting inclusion criteria. In general a non-significant increase in N/L ratio was observed with increasing tumor size and stage ( $p > 0.05$ ) in larynx carcinoma.<sup>3</sup> The N/L ratio was found to be significantly higher in larynx carcinoma compared to control group ( $p = 0.004$ ).

Tu et al The optimal cutoff value of the NLR was 2.17. In the  $NLR \leq 2.17$  group, the 1-, 3-, and 5-year DFS rates were 88.2, 73.9 and 69.1 %, respectively, while in the  $NLR > 2.17$  group, the DFS rates were 83.0, 54.6 and 49.2 %, respectively.<sup>4</sup> Correspondingly, the 1-, 3-, and 5-year OS rates were 98.9, 85.1 and 77.4 % in the  $NLR \leq 2.17$  group and 97.9, 63.8 and 53.3 % in the  $NLR > 2.17$  group, respectively. The multivariate Cox proportional hazard model analysis showed that  $NLR > 2.17$  was a prognostic factor for both DFS [hazard ratio (HR)=1.869; 95 % confidence interval (CI) 1.078–3.243;  $p = 0.026$ ] and OS (HR=2.177; 95 % CI 1.208–3.924;  $p = 0.010$ ) showed that elevated preoperative NLR was an independent predictor of poor prognosis for patients with LSCC after surgical resection.

Zeng et al studied the median (range) follow-up of 45 months, the median neutrophil-to-lymphocyte ratio was 3.02.<sup>5</sup> The high neutrophil-to-lymphocyte ratio group (neutrophil-to-lymphocyte ratio  $> 3.0$ ) contained 69 patients and the low neutrophil-to-lymphocyte ratio group (neutrophil-to-lymphocyte ratio  $< 3.0$ ) contained 46 patients. The low neutrophil-to-lymphocyte ratio group patients had a significantly higher chemoradiotherapeutic disease control rate (86.96 versus 69.57%,  $p = 0.031$ ). Forty-six patients had a low neutrophil-to-lymphocyte ratio ( $< 3.0$ ) before chemoradiotherapy and their progression-free survival and 75% overall survival were significantly better than that of the high neutrophil-to-lymphocyte ratio patients ( $p = 0.015$ ,  $p = 0.045$ ). Multivariate analysis showed that neutrophil-to-lymphocyte ratio and N stage were independent prognostic indicators for progression-free survival (with a hazard ratio of 1.79,  $p = 0.003$  and a hazard ratio of 1.28,  $p = 0.034$ ) and overall survival (with a hazard ratio of 1.51,  $p = 0.029$  and a hazard ratio of 1.21,  $p = 0.043$ ), respectively.

Fu et al take Four-hundred twenty patients in this study. Patients with an  $NLR \geq 2.59$  showed a significantly lower CSS (P%4.014) and OS (P%4.032) than patients with an  $NLR < 2.59$ .<sup>6</sup> The Cox proportional multivariate hazard model showed that a higher preoperative NLR was independently correlated with a poor CSS and OS, with hazard ratios of 1.42 (95% confidence interval [CI] 1.06–1.91, P%4.018) and 1.31 (95% CI 1.00–1.71, P%4.046), respectively. The

NLR may be an independent prognostic marker for CSS and OS in patients with advanced LSCC undergoing TL.

Kum et al studied retrospective study was performed on 209 patients admitted to a tertiary referral center with laryngeal lesions and undergoing biopsies to establish their histopathological diagnosis.<sup>7</sup> We reviewed the patient files for their clinical, histopathological and laboratory data. The patients were divided into three groups according to their histopathological findings, as BLL, PLL and LSCC groups. The patients in the PLL group were also divided into three subgroups as mild, moderate and severe dysplasia/ carcinoma in situ (CIS) subgroups. The groups were compared for NLR and the other laboratory data. The mean NLRs of the BLL, PLL and the LSCC groups were  $2.12 \pm 0.86$ ,  $2.32 \pm 0.68$  and  $3.46 \pm 1.51$ , respectively, and the difference was statistically significant ( $p=0.001$ ). The mean NLRs of the patients with PLL and LSCC were significantly higher than the patients with BLL ( $p=0.031$  and  $p=0.001$ , respectively). The mean NLRs were similar among mild dysplasia, moderate dysplasia and severe dysplasia / CIS groups ( $p>0.05$ ).

Hsueh et al studied 979 patients with LSCC were enrolled in our study. Preoperative neutrophils, platelets, lymphocytes, monocytes, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were analyzed.<sup>8</sup> Besides well-established clinicopathological prognostic factors, we evaluated the independent prognostic relevance of these hematological parameters by Cox regression models in disease-free survival (DFS) and cancer-specific survival (CSS). We found patients in the highest tertile of NLR ( $>2.40$ ), PLR ( $>111.00$ ) were at significantly higher risk of DFS and CSS ( $p<0.05$ ) compared with those in the lowest tertile after multivariate analysis, whereas presenting significantly higher risk in the lowest tertile of lymphocytes ( $<1.60 \times 10^9/l$ ) and LMR ( $<3.50$ ). Additionally, the tertile category of NLR as well as PLR increased and lymphocytes as well as LMR decreased in shorter DFS and CSS by the Kaplan-Meier method and the log-rank test.

In our study, NLR could be used as a prognostic factor in laryngeal carcinoma. when results were analyzed, significant relationships were monitored between NLR and many prognostic factors.

In our study, When NLR group compare to tumour regression at the end of follow up, Low NLR group show high tumour regression than High NLR.

When the relationship of Tumor negative prognostic score (QOL) with the NLR group was examined, significant results were observed. QOL was significantly higher in patients with High NLR group. This finding is very important. Because NLR is easily available from laboratory test, not costly and a universal biomarker.

In our study, When the relationship of NLR group with the percent of patients survive at the end of follow up, significant results were observed. All 30 patients of Low NLR group survive while 8 patients out of 35 of high NLR died at the end of follow up.

NLR was significantly higher in people who were smoker and alcohol users. The significant correlation of NLR with all these prognostic factors supposed that NLR can be used in laryngeal cancer as a prognostic factor due to the significant correlation of NLR with all these prognostic factors.

### Limitations

This study had some limitations, the questionnaire for assessment of QOL was self-designed and need to be standardized. The eight domains of QOL questionnaire cannot practically assessed the severity of symptoms individually on same 4-point Likert scale. While filling the questionnaire the possibility of subjective and interviewer bias cannot be ruled out completely. The study is of short term and Long term study is required for better assessment of result statistically.

### CONCLUSION

It was concluded that pretreatment NLR is a acceptable prognostic tool in carcinoma larynx. High NLR was associated with poor prognosis and low NLR was associated with better prognosis. Patients with High NLR show less tumor regression (50%) as compare to Low NLR. It was also concluded in our study that patients with pretreatment high NLR show high mortality. QOL score (Tumor negative prognostic score) is high in high NLR. Patients having high NLR also have addiction of smoking and alcohol. It was concluded in our study that patient with late carcinoma and high NLR have more QOL (Tumor negative prognostic score) as compare to early carcinoma and high NLR while patients with late carcinoma and low NLR have more QOL as compare to patient with early carcinoma and low NLR.

*Funding: No funding sources*

*Conflict of interest: None declared*

*Ethical approval: The study was approved by the Institutional Ethics Committee*

### REFERENCES

1. Eskiizmir G, Uz U, Onur E. The evaluation of pretreatment neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio in patients with laryngeal neoplasms. *Braz J Otorhinolaryngol.* 2018.
2. Engin BHS, Ulas EAG, Alabalık Fazıl Emre O' zkart Mehmet Akdag' I 'smail Topc. Neutrophil–Lymphocyte Ratio as a Prognostic Factor in Laryngeal Carcinoma. *Indian J Otolaryngol Head Neck Surg.* 2018;70(2):175-9.

3. Duzlu M, Karamert R, Tutar H, Karaloglu F, Sahin M, Cevizci R. Neutrophil-lymphocyte ratio findings and larynx carcinoma: a preliminary study in Turkey. *Asian Pac J Cancer Prev.* 2015;16(1):351.
4. Tu XP, Qiu QH, Chen LS, Luo XN, Lu ZM, Zhang SY, et al. Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma. *BMC Cancer.* 2015;15:743.
5. Zeng YC, Chi F, Xing R, Xue M, Wu LN, Tang MY et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. *Japanese Journal of Clinical Oncology.* 2016;46(2):126-31.
6. Fu Y, Liu W, Ouyang D, Yang A, Zhang Q. Preoperative neutrophil-to-lymphocyte ratio predicts long-term survival in patients undergoing total laryngectomy with advanced laryngeal squamous cell carcinoma: a single-center retrospective study. *Medicine (Baltimore).* 2016;95(6):e2689.
7. Kum RO, Ozcan M, Baklaci D, Kum NY, Yilmaz YF, Gungor V, et al. Elevated Neutrophil-to-Lymphocyte Ratio in Squamous Cell Carcinoma of Larynx Compared to Benign and Precancerous Laryngeal Lesions. *Asian Pacific J Cancer Prevent.* 2014;15(17):7351-5.
8. Hsueh C, Tao L, Zhang M, Cao W, Gong H, Zhou J et al. The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell cancer. *Oncotarget.* 2017;8(36):60514-27.

**Cite this article as:** Sharma A, Kanaujia SK, Kaushik S, Srivastava A. Neutrophil-lymphocyte ratio as a prognostic tool for the evaluation of laryngeal carcinoma. *Int J Otorhinolaryngol Head Neck Surg* 2021;7:627-32.